{{Rsnum
|rsid=8042404
|Chromosome=15
|position=31387813
|Orientation=plus
|GMAF=0.3884
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(A;A)
|geno2=(A;G)
|geno3=(G;G)
}}{{ population diversity
| geno1=(A;A)
| geno2=(A;G)
| geno3=(G;G)
| CEU | 8.0 | 32.7 | 59.3
| HCB | 21.2 | 46.0 | 32.8
| JPT | 15.0 | 46.0 | 38.9
| YRI | 22.4 | 51.7 | 25.9
| ASW | 22.8 | 43.9 | 33.3
| CHB | 21.2 | 46.0 | 32.8
| CHD | 11.9 | 51.4 | 36.7
| GIH | 5.0 | 36.6 | 58.4
| LWK | 25.7 | 56.9 | 17.4
| MEX | 19.0 | 60.3 | 20.7
| MKK | 16.7 | 53.8 | 29.5
| TSI | 7.8 | 44.1 | 48.0
| HapMapRevision=28
}}{{PharmGKB
|RSID=rs8042404
|Name_s=
|Gene_s=FAM189A1
|Feature=
|Evidence=PubMed ID:17537913
|Annotation=Risk or phenotype-associated allele: not stated Phenotype: Using a Quantitative Transmission Disequilibrium Test (QTDT), this variant was significantly associated with etoposide toxicity based upon IC50 values in cell lines from 30 parent-child trios. Study size: 87. Study population/ethnicity: 87 European descent Caucasians. Significance metric(s): p = 0.00005. Type of association: FA; GN.
|Drugs=etoposide
|Drug Classes=
|Diseases=Drug Toxicity
|Curation Level=Curated
|PharmGKB Accession ID=PA165109421
}}

{{GET Evidence
|impact=pharmacogenetic
|qualified_impact=Insufficiently evaluated pharmacogenetic
|inheritance=unknown
|quality_scores=Array
|dbsnp_id=rs8042404
|overall_frequency_n=44
|overall_frequency_d=126
|overall_frequency=0.349206
|n_genomes=37
|n_genomes_annotated=0
|n_haplomes=44
|n_articles=1
|n_articles_annotated=0
|in_pharmgkb=Y
|autoscore=1
|webscore=N
}}

{{on chip | 23andMe v1}}
{{on chip | 23andMe v2}}
{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | Affy GenomeWide 6}}
{{on chip | FTDNA2}}
{{on chip | HumanOmni1Quad}}
{{on chip | Illumina Human 1M}}